Trevi Therapeutics Initiated at Buy by Rodman & Renshaw
Rodman & Renshaw Initiates Coverage On Trevi Therapeutics With Buy Rating, Announces Price Target of $7
Rodman & Renshaw Initiates Trevi Therapeutics(TRVI.US) With Buy Rating, Announces Target Price $7
Rodman & Renshaw analyst Elemer Piros initiates coverage on $Trevi Therapeutics(TRVI.US)$ with a buy rating, and sets the target price at $7.According to TipRanks data, the analyst has a success rate
12 Health Care Stocks Moving In Thursday's After-Market Session
Form 144 | Trevi Therapeutics(TRVI.US) Officer Proposes to Sell 136.62K in Common Stocks
SEC FILLINGS DISCLOSED/ May 29, $Trevi Therapeutics(TRVI.US)$ Officer SCIASCIA THOMAS intends to sell 53,368 shares of its common stock on May 29, with a total market value of approximately $136.62K.
Trevi Therapeutics(TRVI.US) Officer Sells US$71,575.78 in Common Stock
$Trevi Therapeutics(TRVI.US)$ Officer GOOD JENNIFER L sold 25,037 shares of common stock on May 20, 2024 at an average price of $2.8588 for a total value of $71,575.78.Source: Announcement What is sta
Trevi Therapeutics(TRVI.US) Officer Sells US$13,276.2 in Common Stock
$Trevi Therapeutics(TRVI.US)$ Officer GOOD JENNIFER L sold 4,578 shares of common stock on May 10, 2024 at an average price of $2.9 for a total value of $13,276.2.Source: Announcement What is statemen
Buy Rating Affirmed for Trevi Therapeutics Amid Promising Clinical Advances and Solid Financial Position
Analysts Are Bullish on These Healthcare Stocks: MariMed (MRMD), Trevi Therapeutics (TRVI)
Trevi Therapeutics to Participate in Upcoming Conferences
Trevi Therapeutics Price Target Maintained With a $8.00/Share by Needham
Analysts Are Bullish on These Healthcare Stocks: Trevi Therapeutics (TRVI), Neurogene (NGNE)
Trevi Therapeutics Shares Are Trading Lower After the Company Reported Worse-than-expected Q1 GAAP EPS Results.
Trevi Therapeutics | 10-Q: Quarterly report
Trevi Therapeutics to Report First Quarter 2024 Financial Results and Provide a Corporate Update on May 7, 2024
Trevi Therapeutics to Present Phase 2 Results of Haduvio for Chronic Cough at ATS 2024 Conference
Needham: Reiterates the Trevi Therapeutics (TRVI.US) rating, adjusted from buy to buy, with a target price of $8.00.
Needham: Reiterates the Trevi Therapeutics (TRVI.US) rating, adjusted from buy to buy, with a target price of $8.00.
Trevi Therapeutics Analyst Ratings
CALM,PLAY and VNDA Are Among After Hour Movers
Analysts Offer Insights on Healthcare Companies: Trevi Therapeutics (TRVI), Oculis Holding (OCS) and Quanterix (QTRX)